Cargando…
Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial
BACKGROUND: Nutrition therapy is the cornerstone of treating diabetes mellitus. The inclusion of fish (particularly oily fish) at least two times per week is recommended by current international dietary guidelines for type 2 diabetes. In contrast to a large number of human studies examining the effe...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836051/ https://www.ncbi.nlm.nih.gov/pubmed/27090218 http://dx.doi.org/10.1186/s12944-016-0245-0 |
_version_ | 1782427706527318016 |
---|---|
author | Balfegó, Mariona Canivell, Silvia Hanzu, Felicia A. Sala-Vila, Aleix Martínez-Medina, Margarita Murillo, Serafín Mur, Teresa Ruano, Elena G. Linares, Francisca Porras, Nuria Valladares, Silvia Fontalba, Maria Roura, Elena Novials, Anna Hernández, Cristina Aranda, Gloria Sisó-Almirall, Antoni Rojo-Martínez, Gemma Simó, Rafael Gomis, Ramon |
author_facet | Balfegó, Mariona Canivell, Silvia Hanzu, Felicia A. Sala-Vila, Aleix Martínez-Medina, Margarita Murillo, Serafín Mur, Teresa Ruano, Elena G. Linares, Francisca Porras, Nuria Valladares, Silvia Fontalba, Maria Roura, Elena Novials, Anna Hernández, Cristina Aranda, Gloria Sisó-Almirall, Antoni Rojo-Martínez, Gemma Simó, Rafael Gomis, Ramon |
author_sort | Balfegó, Mariona |
collection | PubMed |
description | BACKGROUND: Nutrition therapy is the cornerstone of treating diabetes mellitus. The inclusion of fish (particularly oily fish) at least two times per week is recommended by current international dietary guidelines for type 2 diabetes. In contrast to a large number of human studies examining the effects of oily fish on different cardiovascular risk factors, little research on this topic is available in patients with type 2 diabetes. The aims of this pilot study were to investigate the effects of a sardine-enriched diet on metabolic control, adiponectin, inflammatory markers, erythrocyte membrane fatty acid (EMFA) composition, and gut microbiota in drug-naïve patients with type 2 diabetes. METHODS: 35 drug-naïve patients with type 2 diabetes were randomized to follow either a type 2 diabetes standard diet (control group: CG), or a standard diet enriched with 100 g of sardines 5 days a week (sardine group: SG) for 6 months. Anthropometric, dietary information, fasting glycated hemoglobin, glucose, insulin, adiponectin, inflammatory markers, EMFA and specific bacterial strains were determined before and after intervention. RESULTS: There were no significant differences in glycemic control between groups at the end of the study. Both groups decreased plasma insulin (SG: −35.3 %, P = 0.01, CG: −22.6 %, P = 0.02) and homeostasis model of assessment - insulin resistance (HOMA-IR) (SG: −39.2 %, P = 0.007, CG: −21.8 %, P = 0.04) at 6-months from baseline. However only SG increased adiponectin in plasma compared to baseline level (+40.7 %, P = 0.04). The omega-3 index increased 2.6 % in the SG compared to 0.6 % in the CG (P = 0.001). Both dietary interventions decreased phylum Firmicutes (SG and CG: P = 0.04) and increased E. coli concentrations (SG: P = 0.01, CG: P = 0.03) at the end of the study from baseline, whereas SG decreased Firmicutes/Bacteroidetes ratio (P = 0.04) and increased Bacteroides-Prevotella (P = 0.004) compared to baseline. CONCLUSIONS: Although enriching diet with 100 g of sardines 5 days a week during 6 months to a type 2 diabetes standard diet seems to have neutral effects on glycemic control in drug-naïve patients with type 2 diabetes, this nutritional intervention could have beneficial effects on cardiovascular risk. Furthermore, both dietary interventions decreased HOMA-IR and altered gut microbiota composition of drug-naïve patients with type 2 diabetes. TRIAL REGISTRATION: Trial number and name of the registry: NCT02294526, ClinicalTrials.gov ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12944-016-0245-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4836051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48360512016-04-20 Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial Balfegó, Mariona Canivell, Silvia Hanzu, Felicia A. Sala-Vila, Aleix Martínez-Medina, Margarita Murillo, Serafín Mur, Teresa Ruano, Elena G. Linares, Francisca Porras, Nuria Valladares, Silvia Fontalba, Maria Roura, Elena Novials, Anna Hernández, Cristina Aranda, Gloria Sisó-Almirall, Antoni Rojo-Martínez, Gemma Simó, Rafael Gomis, Ramon Lipids Health Dis Research BACKGROUND: Nutrition therapy is the cornerstone of treating diabetes mellitus. The inclusion of fish (particularly oily fish) at least two times per week is recommended by current international dietary guidelines for type 2 diabetes. In contrast to a large number of human studies examining the effects of oily fish on different cardiovascular risk factors, little research on this topic is available in patients with type 2 diabetes. The aims of this pilot study were to investigate the effects of a sardine-enriched diet on metabolic control, adiponectin, inflammatory markers, erythrocyte membrane fatty acid (EMFA) composition, and gut microbiota in drug-naïve patients with type 2 diabetes. METHODS: 35 drug-naïve patients with type 2 diabetes were randomized to follow either a type 2 diabetes standard diet (control group: CG), or a standard diet enriched with 100 g of sardines 5 days a week (sardine group: SG) for 6 months. Anthropometric, dietary information, fasting glycated hemoglobin, glucose, insulin, adiponectin, inflammatory markers, EMFA and specific bacterial strains were determined before and after intervention. RESULTS: There were no significant differences in glycemic control between groups at the end of the study. Both groups decreased plasma insulin (SG: −35.3 %, P = 0.01, CG: −22.6 %, P = 0.02) and homeostasis model of assessment - insulin resistance (HOMA-IR) (SG: −39.2 %, P = 0.007, CG: −21.8 %, P = 0.04) at 6-months from baseline. However only SG increased adiponectin in plasma compared to baseline level (+40.7 %, P = 0.04). The omega-3 index increased 2.6 % in the SG compared to 0.6 % in the CG (P = 0.001). Both dietary interventions decreased phylum Firmicutes (SG and CG: P = 0.04) and increased E. coli concentrations (SG: P = 0.01, CG: P = 0.03) at the end of the study from baseline, whereas SG decreased Firmicutes/Bacteroidetes ratio (P = 0.04) and increased Bacteroides-Prevotella (P = 0.004) compared to baseline. CONCLUSIONS: Although enriching diet with 100 g of sardines 5 days a week during 6 months to a type 2 diabetes standard diet seems to have neutral effects on glycemic control in drug-naïve patients with type 2 diabetes, this nutritional intervention could have beneficial effects on cardiovascular risk. Furthermore, both dietary interventions decreased HOMA-IR and altered gut microbiota composition of drug-naïve patients with type 2 diabetes. TRIAL REGISTRATION: Trial number and name of the registry: NCT02294526, ClinicalTrials.gov ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12944-016-0245-0) contains supplementary material, which is available to authorized users. BioMed Central 2016-04-18 /pmc/articles/PMC4836051/ /pubmed/27090218 http://dx.doi.org/10.1186/s12944-016-0245-0 Text en © Balfegó et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Balfegó, Mariona Canivell, Silvia Hanzu, Felicia A. Sala-Vila, Aleix Martínez-Medina, Margarita Murillo, Serafín Mur, Teresa Ruano, Elena G. Linares, Francisca Porras, Nuria Valladares, Silvia Fontalba, Maria Roura, Elena Novials, Anna Hernández, Cristina Aranda, Gloria Sisó-Almirall, Antoni Rojo-Martínez, Gemma Simó, Rafael Gomis, Ramon Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial |
title | Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial |
title_full | Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial |
title_fullStr | Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial |
title_full_unstemmed | Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial |
title_short | Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial |
title_sort | effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4836051/ https://www.ncbi.nlm.nih.gov/pubmed/27090218 http://dx.doi.org/10.1186/s12944-016-0245-0 |
work_keys_str_mv | AT balfegomariona effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT canivellsilvia effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT hanzufeliciaa effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT salavilaaleix effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT martinezmedinamargarita effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT murilloserafin effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT murteresa effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT ruanoelenag effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT linaresfrancisca effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT porrasnuria effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT valladaressilvia effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT fontalbamaria effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT rouraelena effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT novialsanna effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT hernandezcristina effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT arandagloria effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT sisoalmirallantoni effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT rojomartinezgemma effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT simorafael effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial AT gomisramon effectsofsardineenricheddietonmetaboliccontrolinflammationandgutmicrobiotaindrugnaivepatientswithtype2diabetesapilotrandomizedtrial |